Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Silverman TB, Kuperman GJ, Vanegas A, Sin M, Dimond J, Crew KD, Kukafka R. An applied framework in support of shared decision making about BRCA genetic testing. AMIA Annu Symp Proc. 2018 Dec 5;2018:961-9.
Sin M, McGuinness JE, Trivedi MS, Vanegas A, Silverman TB, Crew KD, Kukafka R. Automatic genetic risk assessment calculation using breast cancer family history data from the EHR compared to self-report. AMIA Annu Symp Proc. 2018 Dec 5;2018:970-8.
Coe AM, Ueng W, Vargas JM, David R, Vanegas A, Infante K, Trivedi M, Yi H, Dimond J, Crew KD, Kukafka R. Usability testing of a web-based decision aid for breast cancer risk assessment among multi-ethnic women. AMIA Annu Symp Proc. 2017 Feb 10;2016:411-20.
Hutchison RW, Anastassopoulos K, Vallow S, Mordin M, Olson W, Hewitt D, Sikirica V. Intravenous patient-controlled analgesia pump and reservoir logistics: results from a multicenter questionnaire. Hosp Pharm. 2007 Nov 1;42(11):1036-44.